ACEA Therapeutics
aceatherapeutics.com
Actively hiring
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Qiming Venture Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 15, 2019
Took on debt financing $18M · SEC Form D
Feb 22, 2018
Took on debt financing $7.9M · SEC Form D
2017
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Mar 2019 | $18M | — | SEC Form D |
| Debt Financing | Feb 2018 | $7.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | ACEA Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Xiao XuExecutive Officer, DirectorSEC Form D
Xiaobo WangExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Qiming Venture Partners Similar startupsby what they do, their industry and backers
"We are committed to creating the future of oncology by developing innovative therapies inducing autophagy to address unmet medical needs".
Cell and Gene Therapy. Cure Genetics Committed to the development of gene and cell therapy for oncology and genetic diseases Cure Genetics…
Overview. Ambros Therapeutics, headquartered in San Diego, California, is a clinical-stage biotechnology company focused on the development…
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing…
ABOUT US CONNECTA Therapeutics S.L. is a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address…
Clarity is a clinical stage company developing products to address the growing need for the use of radiopharmaceuticals in oncology.
Overview
ACEA Therapeutics is a clinical stage pharmaceutical company with a diverse product portfolio to address unmet medical needs in cancer, autoimmune disease, and Covid-19. Alongside a... Read more ».
News
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
--Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, tod
Read more
Report
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO (Olgotrelvir) or placebo. The primary endpoint was time to sustained recovery of 11 COVID-
Read more
Report
Abivertinib Shows Promise Treating Marginal Zone Lymphoma
The post Abivertinib Shows Promise Treating Marginal Zone Lymphoma appeared first on ACEA.
Read more
Report
Abivertinib Produces Responses in Relapsed/Refractory Marginal Zone Lymphoma
The post Abivertinib Produces Responses in Relapsed/Refractory Marginal Zone Lymphoma appeared first on ACEA.
Read more
Report
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19
The post Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 appeared first on ACEA.
Read more
Report
Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock
Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock. Sorrento will also pay the ACEA up to $450 million in additional milestone payments and 5-10% roya
Read more
Report
Learn about our Product Candidates
OlgotrelvirLearn More AbivertinibLearn More AC0058Learn More STI-6129Learn More AC0939Learn More AC-PROLearn More STI-1492Learn More The post Learn about our Product Candidates appeared first on ACEA.
Read more
Report
Report
Report
Report
Show more news
People
Xiao Xu
Executive Officer, Director
Xiaobo Wang
Executive Officer, Director
Joyce Hsu
Director
Feng Lin
Director
Mang Yu
Director
Jixun Lin
Director
Ng Chi Keung
Director
Lin Li
Director
Stephen Lin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
San Diego
United States
HQ
Acea Therapeutics, Inc.
4955 Directors Place, San Diego, CA 92121 USA
Hangzhou
China
Engineering / R&D
Hangzhou ACEA Pharmaceuticals Research
Floor 4, Building 3, No.208, Zhenzhong Road,, West Lake District, Hangzhou, Zhejiang, China 310030
Quzhou
China
Regional office
Zhejiang ACEA Pharmaceuticals
11 Huangyin North Road, Quzhou, Zhejiang, China 324000